+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation

Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation

Journal of Clinical Oncology 23(17): 3897-3905

The nucleoside analog 5-aza-2'-deoxycytidine (5-aza-CdR, decitabine) is a potent inhibitor of DNA methylation in vitro. Cellular treatment with this agent induces the re-expression of methylation-silenced genes. It remains unclear to what extent this compound inhibits DNA methylation in vivo. A clinical study was designed to examine the molecular effects and toxicity of a continuous 1-week intravenous infusion of decitabine in solid tumor patients. Ten patients with refractory solid tumors were included in this study. Decitabine was administered at 2 mg/m(2)/d [DOSAGE ERROR CORRECTED] via continuous infusion for 168 hours. Quantitative polymerase chain reaction and high performance liquid chromatography were utilized to measure promoter-specific and global DNA methylation in peripheral-blood cells before and after treatment. Transient grade III/IV neutropenia (two patients) and grade II thrombocytopenia (one patient) was observed at the lowest planned dose step (2 mg/m2/d for 7 days). Nonhematologic toxicities were not observed. Quantitative polymerase chain reaction demonstrated significant MAGE-1 promoter hypomethylation by 14 days after the start of treatment in all 13 treatment cycles examined. Significant genomic DNA hypomethylation was also seen by day 14 in 11 of 13 treatment cycles analyzed. Genomic DNA methylation reverted to baseline levels by 28 to 35 days after the start of treatment, demonstrating that inhibition of DNA methylation by decitabine is transient. A 168-hour continuous infusion of decitabine is well tolerated and results in the inhibition of promoter-specific and genomic DNA methylation in vivo. This treatment schedule is suitable for evaluation of decitabine in combination with agents whose activity may be enhanced by the reversal of DNA methylation-mediated gene silencing.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 048993198

Download citation: RISBibTeXText

PMID: 15753459

DOI: 10.1200/jco.2005.06.118

Related references

Impact of Global and Gene-Specific DNA Methylation in de Novo or Relapsed Acute Myeloid Leukemia Patients Treated with Decitabine. Asian Pacific Journal of Cancer Prevention 17(1): 431-437, 2016

The significance of DNA methylation patterns: promoter inhibition by sequence-specific methylation is one functional consequence. Philosophical Transactions of the Royal Society of London. Series B Biological Sciences 326(1235): 253-265, 1990

Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers. Bmc Cancer 16: 589, 2016

Complete cytogenetic remission after decitabine treatment in a patient with secondary AML harbouring high p15INK4b gene methylation and high global DNA methylation. Annals of Hematology 88(3): 275-277, 2009

Global, comparative analysis of tissue-specific promoter CpG methylation. Genomics 90(3): 314-323, 2007

Global and gene-specific promoter methylation analysis in primary hyperparathyroidism. Epigenetics 8(6): 646-655, 2013

Promoter-specific modulation of insulin-like growth factor II genomic imprinting by inhibitors of DNA methylation. Journal of Biological Chemistry 271(30): 18253-18262, 1996

The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma. Plos one 6(8): E23332, 2011

Antineoplastic effects of decitabine, an inhibitor of DNA promoter methylation, in adrenocortical carcinoma cells. Archives of Surgery 145(3): 226-232, 2010

Inhibition of DNA methylation by continuous infusion of 5-aza-2deoxycitidine A Phase I study with molecular goals. Proceedings of the American Association for Cancer Research Annual Meeting 43: 1130, 2002

Inhibition of DNA methylation by continuous infusion of 5-Aza-2-deoxycytidine A phase I study with molecular goals. Journal of Investigative Dermatology 117(2): 538, 2001

Quantitative global and gene-specific promoter methylation in relation to biological properties of neuroblastomas. Bmc Medical Genetics 13: 83, 2012

Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients. Clinical Cancer Research 17(12): 4177-4186, 2011

Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer. Clinical Cancer Research 14(11): 3283-3290, 2008

Mapping promoter regions that are hypersensitive to methylation-mediated inhibition of transcription: application of the methylation cassette assay to the Epstein-Barr virus major latency promoter. Journal of Virology 71(9): 6445-6454, 1997